Systemic inflammation in recessive dystrophic epidermolysis bullosa: a five-year longitudinal study
5 March 2026An evaluation of prademagene zamikeracel for the treatment of recessive dystrophic epidermolysis bullosa
18 March 2026Orphanet J Rare Dis. 2026 Mar 7. doi: 10.1186/s13023-026-04295-5. Epub ahead of print. PMID: 41794696
Characterisation of the wound microbiome and antimicrobial resistance profiles in clinical isolates from epidermolysis bullosa patients.
Authors: Amsalu A, Haidari H, Mirco B, Rudolph-Stringer V, Walter S, Antipov A, Murrell DF, Kopecki Z.
Affiliation:
- Future Industries Institute, University of South Australia, Mawson Lakes, SA, 5095, Australia.
- College of Medicine and Public Health, Flinders University, Bedford Park, SA, 5042, Australia.
- Department of Dermatology, St. George Hospital, Sydney, Australia.
- Faculty of medicine, University of New South Wales, Sydney, Australia.
- Future Industries Institute, University of South Australia, Mawson Lakes, SA, 5095, Australia. zlatko.kopecki@unisa.edu.au.
Abstract:
No abstract available
Keywords: Staphylococcus aureus; 16S rRNA sequencing; Antimicrobial resistance; Blistered skin; Chronic wound; Epidermolysis bullosa; Wound microbiome